We report cases, registered in the French national pharmacovigilance database, of fetal death and intrauterine growth retardation in women exposed to triptans during pregnancy. Triptans have vasoconstrictive properties and we wonder about their responsibility for these side effects. The use of triptans and other drugs exhibiting vasoconstrictive properties in pregnant women requires a careful benefits/risks evaluation.
Keywords: Drugs; Fetal death; Intra-uterine growth retardation; Pregnancy; Triptans.
Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.